Asthma is an established and growing market dominated by key brands. However,
competition is growing and generic threats are increasing, such that the
market will become more fragmented. A number of pipeline products, notably
once-daily ICS/LABA combinations, are expected to address unmet needs and have
high clinical and commercial potential.
Features and benefits
Access Datamonitor's independent clinical and commercial assessment of
marketed brands and key pipeline agents for asthma.
Understand what it takes to differentiate a product in asthma treatment
and how the pipeline threatens current market leaders.
Assess how pipeline products compare to each other and how they will
compete with established therapies.
Review important clinical developments for key pipeline agents with
analysis of the latest clinical trial data.
Highlights
Advair (GlaxoSmithKline) was the first ICS/LABA combination to launch but is
expected to come under threat from generics and increasing competition, but
with Phase III trials complete, its follow-on Relovair is on track to become
the first once-daily ICS/LABA, which, if achieved, would ensure that the
company maintains its market dominance.
Several biologics have advanced in the pipeline. Genentech's lebrikizumab is
currently in large Phase III trials looking at exacerbations and AstraZeneca's
tralokinumab and benralizumab are both in Phase II. Biologics could address
unmet needs for subsets of uncontrolled patients, but key opinion leaders
maintain skepticism over their viability.
Despite patent expiries for key ICS/LABA combinations, generics have not yet
entered any of the seven major markets. Datamonitor believes that in the next
couple of years they will launch as branded generics. Lower price discounts
together with patients' hesitation to switch devices will help the brands
resist generic erosion.
Your key questions answered
How do marketed treatments of asthma compare to one another and where will
pipeline agents fit in?
How is GlaxoSmithKline protecting its market position in the face of
increasing competition and looming generic entry?
How can companies position their products at launch in order to compete in
this well established market?
How is asthma treatment expected to change as novel therapies move through
the pipeline?
Figure: Phase III efficacy and safety study for masitinib
Figure: Masitinib - SWOT analysis for asthma, 2012
Figure: Datamonitor's drug assessment summary of masitinib (AB-1010; AB
Science) for asthma, 2012
Figure: Phase II safety study for QMF149
Figure: QMF149 - Phase II trial results
Figure: QMF149 - SWOT analysis for asthma, 2012
Figure: Datamonitor's drug assessment summary of QMF149
(mometasone/indacaterol; Novartis) for asthma, 2012
Product Profiles: Asthma - Key companies act to maintain dominance published by Datamonitor in June 1, 2012. This report consists of Pages: 114 and the price starts from US $ 11400.
